Integris Medtech, a prominent medical technology platform, has recently filed its initial public offering (IPO) papers with the Securities and Exchange Board of India (Sebi). Consequently, this significant move aims to raise between Rs 3,500 crore and Rs 4,000 crore, signaling a major development for the Indian medical device sector.
### Understanding the Integris Medtech IPO Structure
The proposed Integris Medtech IPO includes a fresh issue of equity shares valued at Rs 925 crore. Furthermore, an offer for sale (OFS) involves the divestment of 2.16 crore equity shares by various promoters. Key selling shareholders in the OFS include Evercure Holdings Pte Ltd, Gurmit Singh Chugh, and Punita Sharma.
A primary objective for the fresh issue funds is debt repayment. Specifically, these proceeds will address borrowings by several subsidiaries, including Translumina Therapeutics and Transhealth. Moreover, a portion of the funds will be allocated for general corporate purposes.
### Integris Medtech: A Diversified Medical Technology Player
Co-founded by Gurmit Singh Chugh and Punita Sharma, Integris Medtech boasts extensive expertise. They develop, manufacture, commercialize, and sell a diverse portfolio of medical devices and solutions. Their offerings encompass cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
The company maintains manufacturing facilities across India, Germany, and the Netherlands. Additionally, it collaborates with global manufacturers, distributing medical devices and laboratory solutions in over 65 countries as of June 30, 2025. This global reach highlights its significant presence in the medical technology landscape.
### Financial Performance and Market Valuation
Integris Medtech has demonstrated robust financial growth. Its total income surged by 24% to Rs 1,959.58 crore in FY25, up from Rs 1,582.25 crore in the preceding year. Significantly, the company achieved a profit of Rs 70.6 crore in FY25, marking a positive turnaround from a loss of Rs 4.8 crore in FY24.
This strong financial performance underpins the company’s ambitious valuation targets. Insiders suggest Integris Medtech is eyeing a valuation between Rs 11,000 crore and Rs 13,000 crore post-IPO. Importantly, private equity firm Everstone Capital backs Integris Medtech.
### Role of Merchant Bankers in the Integris Medtech IPO
To facilitate this major public offering, several prominent financial institutions are acting as merchant bankers. These include ICICI Securities, Axis Capital, Citigroup Global Markets India, and IIFL Capital Services. Their involvement underscores the IPO’s scale and importance.
### Frequently Asked Questions
Q1: What is the estimated issue size of the Integris Medtech IPO?
The estimated issue size for the Integris Medtech IPO is projected to be between Rs 3,500 crore and Rs 4,000 crore.
Q2: What will be the primary use of the fresh issue proceeds?
The proceeds from the fresh issue will primarily be utilized for the repayment of debt incurred by its subsidiaries and for general corporate purposes.
Q3: What types of medical devices does Integris Medtech offer?
Integris Medtech provides a broad portfolio including cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. They are particularly known for manufacturing and distributing cardiac stents.
References
- Integris Medtech files IPO papers with Sebi to garner INR 3,500-4,000 cr – ETHealthworld
- Integris Medtech files DRHP with Sebi to raise Rs 3500-4000 crore via IPO – The Economic Times
- Integris Medtech files IPO papers with Sebi to garner ₹3500-4000 cr – Business Standard
- Everstone Capital backed medtech Co, Integris Medtech files DRHP with SEBI for IPO – BioVoiceNews
- Integris Medtech files IPO papers with Sebi to garner Rs 3,500-4,000 cr – Press Trust of India
- Integris Medtech Files DRHP With SEBI for ₹925 Crore IPO – Angel One
- Integris Medtech Files ₹925 Cr IPO DRHP with SEBI – HDFC Sky
- Everstone Capital-backed Integris Medtech files DRHP for ₹925 crore IPO; key details – Fortune India
- Integris Medtech files DRHP with Sebi to raise Rs 3500-4000 crore via IPO – Livemint
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.